Media release 27 July 2026 InMode expands women’s wellness portfolio with acquisition of Viveve patents InMode has further cemented its position as a leader in women’s wellness, purchasing the intellectual property assets of Vieve Medical Inc. Vieve offers safe and effective medical treatment for vaginal laxity and female urinary incontinence. The acquisition of the Viveve patents will expand InMode’s offerings in women’s wellness, which already includes Empower RF, a comprehensive non-surgical platform delivering life-changing women’s treatments, through bipolar radiofrequency (RF) and electrical muscle stimulation (EMS) to treat a broad range of conditions including, urinary incontinence, weak pelvic floor muscles, blood circulation, and pain relief. “Development of products for women’s wellness continues to be a strategic pillar of our long-term growth strategy,” said Moshe Mizray, InMode CEO. “By investing in new patents and licensing rights, InMode is not only strengthening its intellectual property portfolio but is also reaffirming its commitment to commercialising innovative technologies”.  InMode Australia Managing Director, Dennis Cronje said InMode is proud to be expanding in a market where there is increasing demand. “Women are increasingly becoming aware they don’t need to suffer in silence with problems relating to vaginal laxity and the acquisition of Vieve patents means InMode will be able to offer even more solutions”. About InMode  InMode is a leading global provider of innovative medical technologies.  InMode develops, manufactures, and markets devices harnessing novel radiofrequency ("RF") technology. InMode strives to enable new emerging surgical procedures as well as improve existing treatments. InMode has leveraged its medically-accepted minimally-invasive RF technologies to offer a comprehensive line of products across several categories for aesthetic medicine, gynecology, dermatology and ophthalmology.   Media Contact Sarah Forster sarah.forster@inthemediapr.com.au 0408 445 694

AKE FOREST, Calif., Nov. 10, 2020 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMDINMD), a leading global provider of innovative medical technologies, is pleased to share a groundbreaking peer reviewed study, Plume Effect of Fractional Radiofrequency Versus Laser Resurfacing: Considerations in the COVID Pandemic, published in Lasers in Surgery and Medicine, the official Journal of the American Society for Laser Medicine & Surgery (ASLMS). InMode Ltd. (Nasdaq: INMDINMD), a leading global provider of innovative medical technologies, is pleased to share a groundbreaking peer reviewed study, Plume Effect of Fractional Radiofrequency Versus Laser Resurfacing: Considerations in the COVID Pandemic, published in Lasers in Surgery and Medicine, the official Journal of the American Society for Laser Medicine & Surgery (ASLMS). This landmark study, conducted by renowned physicians Drs. Erez Dayan, Spero Theodorou, Jay Burns, Bruce Katz, and Jeffrey Dover, investigates the potential risk of exposure to plume, the pathogenic tissue debris and biological matter that is generated during skin resurfacing procedures. The study objective was to measure the quantity, size, and rate of plume particle emissions produced beyond the ambient environment baseline from two popular technologies, the Erbium: YAG Laser and the Morpheus8 Fractional Radiofrequency device.  Measurements obtained from a commercial-grade particle analyzer indicated a significant difference in the quantity of plume and the particle size produced by each technology. The Erbium: YAG resurfacing laser was found to emit more than four times the particles versus the fractional RF device, which did not emit plume significantly above the ambient baseline. Dr. Spero Theodorou, InMode Chief Medical Officer and Plastic Surgeon commented, "Ensuring optimal safety during these unprecedented times demands heightened vigilance and a thorough assessment of all technologies used in elective procedures.  The aerosolization of pathogenetic particulate material is a medical consideration that is critical to any product evaluation, and the findings of this clinical paper substantiate the safety profile of Morpheus8's unique multi-level subdermal energy deployment."    "Morpheus8's disruptive RF technology continues to redefine fractional remodeling by delivering unprecedented functionality and efficacy to physicians and their patients.  This new study categorically affirms InMode as the premier fractional RF solution," said Shakil Lakhani, President of InMode North America. Red more here

We are extremely pleased to announce that the US Patent and Trademark Office has granted to InMode Patent No. 10.799.285 covering its Morphues8 full body fractional radiofrequency (RF) technology.

INMODE INTRODUCES MORPHEUS 8 BODY WITH MULTI-PULSE BURST TECHNOLOGY. Sydney, Australia, October 23rd, 2020 - InMode Ltd (Nasdaq: INMD) ("InMode"), a leading global provider of innovative medical technologies, is pleased to introduce to the market the Morpheus8 Body Multi-pulse Burst Radiofrequency Vulcanization Technology.   Expanding on the recent launch of the Morpheus8 Body Subdermal Adipose Remodelling Device (SARD), the first and only FDA cleared and TGA listed technology to penetrate tissue with a thermal profile of 8mm, comes Morpheus8 Body multi pulse Burst Technology.  This groundbreaking, industry-first, fractional technology automatically deploys bipolar RF energy to multi-level treatment depths in a single cycle.  The ability to target tissue sequentially at three levels, in millisecond intervals, allows for a significant reduction in treatment times, minimises skin injury, increases treatment uniformity, and enables customised full body fractional procedures beyond anything previously available.  "Morpheus8 Burst RF technology was predicated on the principles of the Vulcanization Process for cross linking rubber molecules to improve elasticity and tensile strength," said Dr. Spero Theodorou, InMode Chief Medical Officer. "Burst mode mediated RF Vulcanization involves a 3-step process, forming cross links between long collagen fiber molecules in a stratified depth range, to brace the Fibro Septal Network (FSN) and ultimately strengthen the overall skin-adipose scaffold. We are very proud to bring this unprecedented, highly efficacious modality to RF fractional treatments." InMode President of North America, Shakil Lakhani, commented, "With the recent launch of Morpheus8 Body, InMode pioneered full body fractional treatments. The subsequent commercialization of Morpheus8 Burst with multi-level energy deployment unequivocally solidifies InMode as the fractional market leader. Our robust innovation pipeline continues to redefine the medical aesthetics industry and further differentiates InMode as the frontrunner for delivering leading-edge treatment solutions." About InMode  InMode is a leading global provider of innovative medical technologies. InMode develops, manufactures, and markets devices harnessing novel radiofrequency technology. InMode strives to enable new emerging surgical procedures as well as improve existing treatments. InMode has leveraged its medically accepted, minimally invasive RF technologies to offer a comprehensive line of products across several categories for plastic surgery, gynaecology, dermatology, otolaryngology and ophthalmology.   For more information about InMode, please visit INMODE

Sydney, Australia, September 17th, 2020 - InMode Ltd (Nasdaq: INMD) ("InMode"), a leading global provider of innovative medical technologies, is pleased to announce the expansion of the unique Morpheus8 RF Microneedling technology by introducing Morpheus8 Body. Morpheus8 Body is the first intelligent, programmable, full body fractional technology to deliver clinically proven radiofrequency (RF) energy up to a thermal depth of 8mm (7mm pin depth plus an additional 1mm heat thermal profile) with its 40 gold coated pins.  As the first and only FDA cleared and TGA listed  technology to penetrate subdermal tissue with a thermal profile of 8mm, the new Morpheus8 Body technology is designed to provide physicians with a faster, bigger and better solution to deliver customisable full body fractional treatments. Based on the success of InMode's proprietary technology, the new Morpheus8 extends its line of Subdermal Adipose Remodelling Devices (SARD). The new Morpheus8 platform is the complete state-of-the-art workstation with dual handpieces and four fractional tips with different microneedle configurations: Prime 12 pin, Resurfacing 24 pin, Morpheus8 24 pin and Body 40 pin. The Morpheus8 platform provides clinics with a standalone solution for fractional RF, ranging from the Morpheus8 Prime for the treatment of delicate areas with high tissue curvature such as the eyes and nasolabial fold, to the Morpheus8 Body for large zones such as the abdomen, thighs and buttocks. Dennis Cronje, Managing Director of InMode Australia, commented "The addition of Morpheus8 Prime and Body provides a complete fractional RF solution unlike anything available currently. These new treatment modalities can provide a customisable, full body solution for each patient. True innovation in the industry has become scarce and this is where InMode will continue to thrive. We are excited about the new treatment capabilities for both our physicians and their patients". Dr. Stephen Mulholland added, "Morpheus8 has become a standard treatment in my clinic. Whether I use it as a stand-alone treatment for tightening and smoothing of the skin or combined with one of my other treatments, it is my go-to treatment for patients looking for significant, but non-surgical, remodelling improvement”.   About InMode  InMode is a leading global provider of innovative medical technologies. InMode develops, manufactures, and markets devices harnessing novel radiofrequency technology. InMode strives to enable new emerging surgical procedures as well as improve existing treatments. InMode has leveraged its medically accepted, minimally invasive RF technologies to offer a comprehensive line of products across several categories for plastic surgery, gynaecology, dermatology, otolaryngology and ophthalmology.    For more information about InMode, please visit www.inmode.com.au

INMODE STEPS UP TO ASSIST THE AESTHETIC INDUSTRY IN CONJUNCTION WITH THE GOVERNMENT’S ECONOMIC STIMULUS PACKAGE.  InMode Australia is committed to the health and well-being of our employees and their families, our customers, partners, and communities. We value our relationship with industry and the part we play in seeing this industry not only survive but thrive through these very challenging times and we are confident that together we will come through this stronger on the other side. We want to reassure you that we remain open for business. Our IT and telecommunication servers and backup servers are securely held both offsite and in the cloud. Any hypothetical scenario where an office shutdown was required would not affect our ability to service you.  In line with the Government’s direction, we are ensuring that our staff follow the advice of health authorities and practice strong hygiene practices, the social distancing laws and the measures in place to reduce the risk to our people and our customers. We are encouraging the use of technology to maintain contact and interaction with our customers through web conferencing, social media interaction, etc. Our commitment to client service will remain unchanged to the extent possible. Our people remain accessible and ready to assist you with any questions or requests you may have.  The Government has made it very clear that we need to maintain a strong economy and position ourselves well for when we come out of this current situation. To this end, the Government has put in place a number of financial incentives to encourage the investment in new technologies prior to the end of this financial year ending June 30, 2020 and InMode Australia has looked to assist in this initiative by reducing the investment cost on a number of technologies, including the latest Evolve platform to meet the Government’s incentive threshold.    Incentives include: The federal government’s “extraordinary” expansion of the instant asset write-off scheme to help mitigate the impact of the coronavirus pandemic on the economy by lifting five-fold, to $150,000, the write-off threshold to businesses with annual turnover of up to $500 million. Businesses have until June 30, 2020 to take advantage of the higher limit. The rules allow businesses to immediately write off the cost of assets under the threshold and claim a tax deduction for the business portion of the expense in the first year the asset is used or installed. The instant asset write-off and accelerated depreciation initiatives, is aimed at encouraging investment and allow small and medium-sized businesses to grow; For medical customers that qualify, InMode has worked closely with a finance provider to offer ‘no repayments and no interest for 12 months’ when investing in InMode technology. That means you are able to invest and take receipt and ownership of the technology, train up your staff in a measured time-frame to ensure their proficient use of the technology, treat existing customers on the latest technology ensuring ongoing income, and be well positioned to take full advantage of the expected upturn by offering clients the latest treatment options in market; InMode plans to host regular ‘Free online education sessions’ for all in industry who would like to take advantage so as to up-skill clinic/practice staff while business may be slow or employees may be offsite. These theory and hands-on sessions will be streamed live and will encourage interaction between the trainer and viewers. All who agree to take the post-session assessment and pass, will be issued with a ‘Certificate of Attendance’ from InMode. We will be looking to engage leading physicians in industry who are willing to offer their time and expertise to further education in this sector; InMode will further be engaging with Financial and Tax experts to deliver via streaming and at no charge, a comprehensive analysis of the incentives being offered by Government and what individuals and businesses can do to maximise their benefits when taking up of these incentives; In order to ensure brand awareness for clinics/practices and to drive consumer foot traffic to businesses, InMode has invested significant resources in celebrity endorsement of the brand and has engaged Paula Abdul as Brand-Ambassador. A continued focus on social media including Instagram, Facebook, YouTube, etc. will be maintained throughout this period.  We look forward to being of assistance to you. Please be assured of our ongoing support through these difficult times and our unwavering commitment to the aesthetic industry and to you, our valued customers. Yours truly, Dennis CronjeManaging Director, InMode Australia